Lantheus Holdings, Inc.LNTH

時価総額

$38.6億

PER

放射性医薬品を中心とする医療用診断・治療事業の最大手。腫瘍向け治療剤や心臓向け診断薬、TechneLite発生器を展開。2022年に資産取得で2.6億ドル前払、2023年に技術企業を買収、2025年1月にPET診断企業を3.5億ドルで買収合意。米国中心にカナダ、欧州、豪州、アジア太平洋、中南米で展開。

概要財務

サマリーテーブルに戻る

	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net income	-	-	-	-	32	-13	-71	28	327	312
Depreciation, amortization and accretion	-	18	19	14	13	25	42	48	60	65
Asset Impairment Charges	-	-	-	-	-	-	-	-	138	-
Asset retirement obligation acceleration	-	-	-	-	-	-	5	0	-	-
Gain on interest rate swap termination	-	-	-	-	-	-	-	5	-	-
Amortization of debt related costs	2	2	1	1	1	0	1	1	4	4
Changes in fair value of contingent assets and liabilities	-	-	-	-	-	-2	72	35	-9	-3
Charges incurred in connection with acquired IPR&D	-	-	-	-	-	-	-	-260	-	-66
Loss on extinguishment of debt	-16	-	-2	-	-3	-	1	-1	-	-
Inventory Write-down	1	1	1	3	2	2	4	7	8	-1
Stock-based compensation	2	3	6	9	12	14	16	29	51	76
Gain on disposal of assets	-	-	-	-	-	-2	15	-	52	8
Unrealized loss on investment in equity securities	-	-	-	-	-	-	-	-	-	-44
Deferred taxes	-	-	-87	6	10	-1	4	-48	-56	-30
Long-term indemnification receivable	-0	0	8	3	-11	2	-7	-10	-4	-
Increase (Decrease) in Other Noncurrent Liabilities	1	1	3	3	-13	3	-8	-12	-3	5
Other	-2	-1	-1	-1	-0	-2	-3	-4	-5	-12
Accounts receivable	0	1	3	4	-0	7	33	128	69	38
Inventory	3	4	10	9	-2	8	4	8	36	3
Other current assets	0	0	0	1	2	-2	0	2	2	-4
Other long-term assets	-	-	-	-	-	-	-	1	-	-
Accounts payable	-2	6	1	-3	3	-4	5	0	17	-9
Accrued expenses and other liabilities	-4	1	5	2	6	-4	16	64	-81	47
Net cash provided by operating activities	-	-	55	61	80	16	54	282	305	545
Capital expenditures	-	-	-	-	-	-	-	18	47	52
Proceeds from sale of assets, net	-	11	1	1	-	-	16	2	98	18
Purchases of investment in equity securities	-	-	-	-	-	-	-	-	-	83
Acquisition of assets, net	-	-	-	-	-	-	-	-	-	81
Acquisition of exclusive license option	-	-	-	-	-	-	-	-	-	28
Net cash (used in) provided by investing activities	-	-	-16	-19	-22	-5	4	-277	6	-226
Proceeds from issuance of common stock	-	51	0	0	1	1	1	1	2	3
Debt issuance costs	6	0	2	-	2	1	-	0	-	-
Proceeds from Issuance of Long-Term Debt	360	-	274	-	199	-	-	558	-	-
Contingent value rights settlement	-	-	-	-	-	-	-	-	4	-
Payments on long-term debt and other borrowings	2	79	287	3	275	15	43	175	1	0
Deferred financing costs	-	-	-	-	-	-	-	2	-	2
Proceeds From Termination Of Derivatives	-	-	-	-	-	-	-	6	-	-
Proceeds from stock option exercises	-	0	3	1	1	0	5	8	4	3
Payments for minimum statutory tax withholding related to net share settlement of equity awards	0	1	3	3	2	2	2	8	14	23
Repurchase of common stock	-	-	-	-	-	-	-	75	-	100
Net cash (used in) provided by financing activities	-	-	-13	-5	-79	-22	-39	312	-13	-119
Effect of foreign exchange rates on cash and cash equivalents	-	-	-	-	0	0	-0	-0	-0	-1
Net increase in cash and cash equivalents and restricted cash	-	-	-	-	-20	-10	18	317	298	199
Interest	-	-	-	16	12	9	6	5	15	15
Income Taxes Paid, Net	0	0	0	0	0	0	0	54	152	154
Capital Expenditures Incurred but Not yet Paid	1	5	3	7	4	2	1	2	7	5
Lease liability settled through transfer of lease	-	-	-	-	-	-	-	-	-	1
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	-	-	-	-	-	-	-	-	29	0